We're doing work with the provinces and territories now to look at issues around a drug formulary. This is obviously a big policy question that all governments have to grapple with, so I can only speak as an official about some of the possible efficiencies. Certainly, there are a number of aspects to a formulary. One of them is what drugs are on the formulary. Almost more importantly, what are the conditions of access? What conditions are actually authorized by the province or territory for access to the drug?
In the work we've done, one of the things we discovered that's actually quite complicated, if you like, is that it's not just a matter of comparing what kinds of drugs are available in each jurisdiction, but under what circumstances the payments will be made.
If we could advance that kind of work and start to have greater harmonization of the drugs available and the manner in which they're used, the conditions of access, that would start to make it a lot easier to have joint negotiations to move forward in a common way to procure these kinds of products. There's a lot to recommend. Working with the provinces and territories to try to have a more harmonized approach, I would say, might be a way to respond.